MedTrace Logo

Insulin Treatment in Cancer Cachexia

NCT00329615 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2009-08-21

No results posted yet for this study

Summary

The study is designed to evaluate whether daily insulin treatment to weight losing cancer patients attenuates progression of cancer cachexia and improves metabolism.

Conditions

  • Cancer Cachexia

Interventions

DRUG

Insulatard, flexpen

Sponsors & Collaborators

  • Swedish Cancer Foundation

    collaborator OTHER

  • Medical Research Council

    collaborator OTHER_GOV

  • Göteborg University

    lead OTHER

Principal Investigators

  • Kent G Lundholm, MD · Department of Surgery, Göteborg University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Completion
2005-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329615 on ClinicalTrials.gov